로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > HMGB1

HMGB1

요약

Name:High Mobility Group Protein B1
Target Synonym:FM1 Gene Product,HMG 1 Protein,HMG-1 Protein,HMG1,Heparin-Binding Protein p30,High Mobility Group Box 1,High-Mobility Group (Nonhistone Chromosomal) Protein 1,High Mobility Group Protein B1,High Mobility Group Protein 1,HMG-1,Sulfoglucuronyl Carbohydrate Binding Protein,Amphoterin,Box Protein 1, High Mobility Group,SBP-1,High-Mobility Group Box 1,DKFZp686A04236,HMGB1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 1 Clinical

제품 리스트 구매

일부의 생물활성 데이터

HM1-H5255-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human HMGB1 Protein, Mouse IgG2a Fc Tag (Cat. No. HM1-H5255) stimulates production of TNF-α in Raw-246.7 cells. The EC50 for this effect is 13.18 μg/mL (Routinely tested).

HM1-H5220-MALS-HPLC
 HMGB1 ELISA

Immobilized Human HMGB1, His Tag (Cat. No. HM1-H5220) at 5 μg/mL (100 μL/well) can bind Human RAGE, Fc Tag with a linear range of 0.078-2.5 μg/mL (Routinely tested).

Synonym Name

HMGB1,HMG1,HMG3,SBP-1

Background

High-mobility group protein B1 (HMGB1) is also known as high-mobility group protein 1 (HMG-1) and amphoterin, is a member of the HMGB family consisting of three members, HMGB1, HMGB2 and HMGB3. HMGB1 is a non-histone architectural chromosomal protein ubiquitously present in all vertebrate nuclei and binds double-stranded DNA without sequence specificity. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. This positions HMGB1 at the intersection of sterile and infectious inflammatory responses. HMGB1 has been studied as a DNA vaccine adjuvant and a target for cancer therapy.

Clinical and Translational Updates

Related Molecule

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Dociparstat sodium ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 Phase 1 Clinical Paringenix Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Myelodysplastic Syndromes; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Leukemia, Myeloid, Acute; Acute Lung Injury Details
SB-17170 SB-17170 Phase 1 Clinical Spark Biopharma Inc Solid tumours Details

This web search service is supported by Google Inc.

totop